Cargando…
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
Purpose. This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC). Methods. In this randomized, open-label, active-controlled, single-center, phase II clinical trial, eligible patients were randomized in a ratio...
Autores principales: | Wang, Leiping, Cao, Jun, Li, Chunlei, Wang, Xiaodong, Zhao, Yannan, Li, Ting, Du, Yiqun, Tao, Zhonghua, Peng, Wenxia, Wang, Biyun, Zhang, Jian, Zhang, Sheng, Wang, Zhonghua, Hu, Xichun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993786/ https://www.ncbi.nlm.nih.gov/pubmed/34633576 http://dx.doi.org/10.1007/s10637-021-01182-7 |
Ejemplares similares
-
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
por: Li, Ling, et al.
Publicado: (2020) -
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
por: Sharman, Jeffrey P., et al.
Publicado: (2019) -
An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
por: Vijayakumar, Jayanthi, et al.
Publicado: (2022) -
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
por: Inoue, Kenichi, et al.
Publicado: (2019) -
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)